Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Влияние секса на нормальное функционирование предстательной железы
Влияние секса на нормальное функционирование предстательной железы
Ершов А.В., Саверская Е.Н. Влияние секса на нормальное функционирование предстательной железы. Consilium Medicum. 2023;25(1):63–68. DOI: 10.26442/20751753.2023.1.202181
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзорной статье анализировалась взаимосвязь сексуальной активности и структурно-функционального состояния предстательной железы (ПЖ). Оценен биомеханизм гормонального воздействия сексуальной активности на ПЖ. Проведен анализ влияния гормонов на функционирование ПЖ. По данным многочисленных исследований установлено, что постоянная сексуальная активность в умеренном количестве снижает риск развития заболеваний ПЖ и является важным методом профилактики органоспецифической патологии. Для коррекции нарушений копулятивной функции при заболеваниях ПЖ целесообразно применение простатических пептидов, обладающих органотропным действием.
Ключевые слова: секс, предстательная железа, андрогены, простатические пептиды
Keywords: sex, prostate, androgens, prostatic peptides
Ключевые слова: секс, предстательная железа, андрогены, простатические пептиды
________________________________________________
Keywords: sex, prostate, androgens, prostatic peptides
Полный текст
Список литературы
1. Сомов А.Н., Суслин С.А. Рак предстательной железы. Эпидемиология, факторы риска и раннее выявление. Профилактическая медицина. 2020;23(3):149-55 [Somov AN, Suslin SA. Prostate cancer. Epidemiology, risk factors and early detection. Profilakticheskaya meditsina. 2020;23(3):149-55 (in Russian)]. DOI:10.17116/profmed202023031149
2. Rider JR, Wilson KM, Sinnott JA, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70(6):974-82. DOI:10.1016/j.eururo.2016.03.027
3. Имшинецкая Л.П. Сексология и андрология. Киев, 1997 [Imshinetskaia LP. Seksologiia i andrologiia. Kiev, 1997 (in Russian)].
4. Тюзиков И.А. Клинико-экспериментальные параллели в патогенезе заболеваний предстательной железы. Современные проблемы науки и образования. 2012;1:114. Режим доступа: www. science-education.ru/101-5476. Ссылка активна на 01.03.2023 [Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;1:114. Available at: www. science-education.ru/101-5476. Accessed: 01.03.2023 (in Russian)].
5. Nankin HR, Calkins JH. Pituitary-gonadal function during sleep in healthy aging men. Clin Endocr Metab. 1986;63:14.
6. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocr. 1981;4:49-61. DOI:10.1111/j.1365-2265.1981.tb00364.x
7. Udry JR, Billy JO, Morris NM, et al. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil Steril. 1985;43(1):90-4.
8. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990;70(3):792-7. DOI:10.1210/jcem-70-3-792
9. Тюзиков И.А., Мартов А.Г., Греков Е.А. Взаимосвязь компонентов метаболического синдрома и гормональных нарушений в патогенезе заболеваний предстательной железы (обзор литературы). Экспериментальная и клиническая урология. 2012;3:39-46 [Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;3:39-46 (in Russian)].
10. Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021;26(23):7141. DOI:10.3390/molecules26237141
11. Oelke M, Bachmann A, Descazeaud A. Guideline on the Management of Male Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obsruction (BPO). 2012;74.
12. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999;140(3):1481-91. DOI:10.1210/endo.140.3.6585
13. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999;83(5):1213-29. DOI:10.1016/s0025-7125(05)70159-0
14. Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology. 2009;150(10):4594-605. DOI:10.1210/en.2008-1591
15. Kester RR, Mooppan UM, Gousse AE, et al. Pharmacological characterization of isolated human prostate [published correction appears in J Urol. 2003 Dec;170(6 Pt 1):2394]. J Urol. 2003;170(3):1032-8. DOI:10.1097/01.ju.0000080440.74266.b1
16. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339-54. DOI:10.1111/j.1464-410X.2005.05831.x
17. Del Bello F, Bonifazi A, Giorgioni G, et al. Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. Eur J Med Chem. 2019;168:461-73. DOI:10.1016/j.ejmech.2019.02.056
18. Franklin RB, Juang HH, Zou J, Costello LC. Regulation of citrate metabolism by androgen in human prostate carcinoma cells. Endocrine. 1995;3(8)603-7.
19. Costello LC, Liu Y, Zou J, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate. 2000;42(3):196-202. DOI:10.1002/(sici)1097-0045(20000215)42:3<196::aid-pros5>3.0.co;2-8
20. Zhang J, Zhang M, Tang J, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49-57. DOI:10.1038/s41391-020-00277-1
21. Silva RS, Lombardi APG, de Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. Int J Biochem Cell Biol. 2018;96:40-50. DOI:10.1016/j.biocel.2018.01.008
22. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1-13. DOI:10.1196/annals.1386.009
23. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-83. DOI:10.1111/j.1743-6109.2010.01991.x
24. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):157-80.
25. Lee SN, Kraska J, Papargiris M, et al. Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Sci Rep. 2021;11(1):6352. DOI:10.1038/s41598-021-85439-4
26. Corona G, Jannini EA, Mannucci E, et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. 2008;5(8):1991-8.
DOI:10.1111/j.1743-6109.2008.00803.x
27. Godoy A, Montecinos VP, Gray DR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab. 2011;300(2):E263-75. DOI:10.1152/ajpendo.00210.2010
28. Kozlowski R, Kershen RT, Siroky MB, et al. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165(3):1019-26.
29. Uckert S, Kuczyk MA. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. Handb Exp Pharmacol. 2011;202:527-42. DOI:10.1007/978-3-642-16499-6_23
30. Comar VA, Petersen CG, Mauri AL, et al. Influence of the abstinence period on human sperm quality: analysis of 2,458 semen samples. JBRA Assist Reprod. 2017;21(4):306-12. DOI:10.5935/1518-0557.20170052
31. Apostolopoulos V, Bojarska J, Chai TT, et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. DOI:10.3390/molecules26020430
32. Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int J Mol Sci. 2022;23(3):1445. DOI:10.3390/ijms23031445
33. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-8. DOI:10.1016/j.drudis.2014.10.003
34. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700-7. DOI:10.1016/j.bmc.2017.06.052
35. Сельков С.А., Петленко С.В., Селькова М.С. Применение препарата простатилен в комплексной терапии хронического простатита, ассоциированного с половыми и репродуктивными нарушениями. Андрология и генитальная хирургия. 2012;3:97-100 [Selkov SA, Petlenko SV, Selkova MS. Use of prostatilene in the combination therapy of chronic prostatitis associated with sexual and reproductive disorders. Andrology and Genital Surgery. 2012;3:97-100 (in Russian)].
36. Ткачук В.Н., Альшукри С., Лоцтан-Медведев А.К. Наш опыт применения витапроста у больных хроническим простатитом. Нефрология. 2005;9(4):84-8 [Tkachuk VN, Al-Shukri A, Lotstan-Medvedev AK. Оur experiences with application of vitaprost in chronic prostatitis patients. Nephrology (Saint-Petersburg). 2005;9(4):84-8 (in Russian)]. DOI:10.24884/1561-6274-2005-9-4-84-88
37. Давидов М.И. Сексуальная дисфункция у больных хроническим простатитом и ее коррекция. Урология. 2020;1:51-8 [Davidov MI. Sexual dysfunction in patients with chronic prostatitis and its correction. Urology. 2020;1:51-8 (in Russian)]. DOI:10.18565/urology.2020.1.51-58
2. Rider JR, Wilson KM, Sinnott JA, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70(6):974-82. DOI:10.1016/j.eururo.2016.03.027
3. Imshinetskaia LP. Seksologiia i andrologiia. Kiev, 1997 (in Russian).
4. Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;1:114. Available at: www. science-education.ru/101-5476. Accessed: 01.03.2023 (in Russian).
5. Nankin HR, Calkins JH. Pituitary-gonadal function during sleep in healthy aging men. Clin Endocr Metab. 1986;63:14.
6. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocr. 1981;4:49-61. DOI:10.1111/j.1365-2265.1981.tb00364.x
7. Udry JR, Billy JO, Morris NM, et al. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil Steril. 1985;43(1):90-4.
8. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990;70(3):792-7. DOI:10.1210/jcem-70-3-792
9. Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;3:39-46 (in Russian).
10. Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021;26(23):7141. DOI:10.3390/molecules26237141
11. Oelke M, Bachmann A, Descazeaud A. Guideline on the Management of Male Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obsruction (BPO). 2012;74.
12. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999;140(3):1481-91. DOI:10.1210/endo.140.3.6585
13. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999;83(5):1213-29. DOI:10.1016/s0025-7125(05)70159-0
14. Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology. 2009;150(10):4594-605. DOI:10.1210/en.2008-1591
15. Kester RR, Mooppan UM, Gousse AE, et al. Pharmacological characterization of isolated human prostate [published correction appears in J Urol. 2003 Dec;170(6 Pt 1):2394]. J Urol. 2003;170(3):1032-8. DOI:10.1097/01.ju.0000080440.74266.b1
16. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339-54. DOI:10.1111/j.1464-410X.2005.05831.x
17. Del Bello F, Bonifazi A, Giorgioni G, et al. Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. Eur J Med Chem. 2019;168:461-73. DOI:10.1016/j.ejmech.2019.02.056
18. Franklin RB, Juang HH, Zou J, Costello LC. Regulation of citrate metabolism by androgen in human prostate carcinoma cells. Endocrine. 1995;3(8)603-7.
19. Costello LC, Liu Y, Zou J, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate. 2000;42(3):196-202. DOI:10.1002/(sici)1097-0045(20000215)42:3<196::aid-pros5>3.0.co;2-8
20. Zhang J, Zhang M, Tang J, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49-57. DOI:10.1038/s41391-020-00277-1
21. Silva RS, Lombardi APG, de Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. Int J Biochem Cell Biol. 2018;96:40-50. DOI:10.1016/j.biocel.2018.01.008
22. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1-13. DOI:10.1196/annals.1386.009
23. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-83. DOI:10.1111/j.1743-6109.2010.01991.x
24. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):157-80.
25. Lee SN, Kraska J, Papargiris M, et al. Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Sci Rep. 2021;11(1):6352. DOI:10.1038/s41598-021-85439-4
26. Corona G, Jannini EA, Mannucci E, et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. 2008;5(8):1991-8.
DOI:10.1111/j.1743-6109.2008.00803.x
27. Godoy A, Montecinos VP, Gray DR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab. 2011;300(2):E263-75. DOI:10.1152/ajpendo.00210.2010
28. Kozlowski R, Kershen RT, Siroky MB, et al. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165(3):1019-26.
29. Uckert S, Kuczyk MA. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. Handb Exp Pharmacol. 2011;202:527-42. DOI:10.1007/978-3-642-16499-6_23
30. Comar VA, Petersen CG, Mauri AL, et al. Influence of the abstinence period on human sperm quality: analysis of 2,458 semen samples. JBRA Assist Reprod. 2017;21(4):306-12. DOI:10.5935/1518-0557.20170052
31. Apostolopoulos V, Bojarska J, Chai TT, et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. DOI:10.3390/molecules26020430
32. Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int J Mol Sci. 2022;23(3):1445. DOI:10.3390/ijms23031445
33. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-8. DOI:10.1016/j.drudis.2014.10.003
34. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700-7. DOI:10.1016/j.bmc.2017.06.052
35. Selkov SA, Petlenko SV, Selkova MS. Use of prostatilene in the combination therapy of chronic prostatitis associated with sexual and reproductive disorders. Andrology and Genital Surgery. 2012;3:97-100 (in Russian).
36. Tkachuk VN, Al-Shukri A, Lotstan-Medvedev AK. Оur experiences with application of vitaprost in chronic prostatitis patients. Nephrology (Saint-Petersburg). 2005;9(4):84-8 (in Russian). DOI:10.24884/1561-6274-2005-9-4-84-88
37. Davidov MI. Sexual dysfunction in patients with chronic prostatitis and its correction. Urology. 2020;1:51-8 (in Russian). DOI:10.18565/urology.2020.1.51-58
2. Rider JR, Wilson KM, Sinnott JA, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70(6):974-82. DOI:10.1016/j.eururo.2016.03.027
3. Имшинецкая Л.П. Сексология и андрология. Киев, 1997 [Imshinetskaia LP. Seksologiia i andrologiia. Kiev, 1997 (in Russian)].
4. Тюзиков И.А. Клинико-экспериментальные параллели в патогенезе заболеваний предстательной железы. Современные проблемы науки и образования. 2012;1:114. Режим доступа: www. science-education.ru/101-5476. Ссылка активна на 01.03.2023 [Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;1:114. Available at: www. science-education.ru/101-5476. Accessed: 01.03.2023 (in Russian)].
5. Nankin HR, Calkins JH. Pituitary-gonadal function during sleep in healthy aging men. Clin Endocr Metab. 1986;63:14.
6. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocr. 1981;4:49-61. DOI:10.1111/j.1365-2265.1981.tb00364.x
7. Udry JR, Billy JO, Morris NM, et al. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil Steril. 1985;43(1):90-4.
8. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990;70(3):792-7. DOI:10.1210/jcem-70-3-792
9. Тюзиков И.А., Мартов А.Г., Греков Е.А. Взаимосвязь компонентов метаболического синдрома и гормональных нарушений в патогенезе заболеваний предстательной железы (обзор литературы). Экспериментальная и клиническая урология. 2012;3:39-46 [Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;3:39-46 (in Russian)].
10. Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021;26(23):7141. DOI:10.3390/molecules26237141
11. Oelke M, Bachmann A, Descazeaud A. Guideline on the Management of Male Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obsruction (BPO). 2012;74.
12. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999;140(3):1481-91. DOI:10.1210/endo.140.3.6585
13. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999;83(5):1213-29. DOI:10.1016/s0025-7125(05)70159-0
14. Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology. 2009;150(10):4594-605. DOI:10.1210/en.2008-1591
15. Kester RR, Mooppan UM, Gousse AE, et al. Pharmacological characterization of isolated human prostate [published correction appears in J Urol. 2003 Dec;170(6 Pt 1):2394]. J Urol. 2003;170(3):1032-8. DOI:10.1097/01.ju.0000080440.74266.b1
16. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339-54. DOI:10.1111/j.1464-410X.2005.05831.x
17. Del Bello F, Bonifazi A, Giorgioni G, et al. Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. Eur J Med Chem. 2019;168:461-73. DOI:10.1016/j.ejmech.2019.02.056
18. Franklin RB, Juang HH, Zou J, Costello LC. Regulation of citrate metabolism by androgen in human prostate carcinoma cells. Endocrine. 1995;3(8)603-7.
19. Costello LC, Liu Y, Zou J, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate. 2000;42(3):196-202. DOI:10.1002/(sici)1097-0045(20000215)42:3<196::aid-pros5>3.0.co;2-8
20. Zhang J, Zhang M, Tang J, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49-57. DOI:10.1038/s41391-020-00277-1
21. Silva RS, Lombardi APG, de Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. Int J Biochem Cell Biol. 2018;96:40-50. DOI:10.1016/j.biocel.2018.01.008
22. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1-13. DOI:10.1196/annals.1386.009
23. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-83. DOI:10.1111/j.1743-6109.2010.01991.x
24. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):157-80.
25. Lee SN, Kraska J, Papargiris M, et al. Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Sci Rep. 2021;11(1):6352. DOI:10.1038/s41598-021-85439-4
26. Corona G, Jannini EA, Mannucci E, et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. 2008;5(8):1991-8.
DOI:10.1111/j.1743-6109.2008.00803.x
27. Godoy A, Montecinos VP, Gray DR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab. 2011;300(2):E263-75. DOI:10.1152/ajpendo.00210.2010
28. Kozlowski R, Kershen RT, Siroky MB, et al. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165(3):1019-26.
29. Uckert S, Kuczyk MA. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. Handb Exp Pharmacol. 2011;202:527-42. DOI:10.1007/978-3-642-16499-6_23
30. Comar VA, Petersen CG, Mauri AL, et al. Influence of the abstinence period on human sperm quality: analysis of 2,458 semen samples. JBRA Assist Reprod. 2017;21(4):306-12. DOI:10.5935/1518-0557.20170052
31. Apostolopoulos V, Bojarska J, Chai TT, et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. DOI:10.3390/molecules26020430
32. Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int J Mol Sci. 2022;23(3):1445. DOI:10.3390/ijms23031445
33. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-8. DOI:10.1016/j.drudis.2014.10.003
34. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700-7. DOI:10.1016/j.bmc.2017.06.052
35. Сельков С.А., Петленко С.В., Селькова М.С. Применение препарата простатилен в комплексной терапии хронического простатита, ассоциированного с половыми и репродуктивными нарушениями. Андрология и генитальная хирургия. 2012;3:97-100 [Selkov SA, Petlenko SV, Selkova MS. Use of prostatilene in the combination therapy of chronic prostatitis associated with sexual and reproductive disorders. Andrology and Genital Surgery. 2012;3:97-100 (in Russian)].
36. Ткачук В.Н., Альшукри С., Лоцтан-Медведев А.К. Наш опыт применения витапроста у больных хроническим простатитом. Нефрология. 2005;9(4):84-8 [Tkachuk VN, Al-Shukri A, Lotstan-Medvedev AK. Оur experiences with application of vitaprost in chronic prostatitis patients. Nephrology (Saint-Petersburg). 2005;9(4):84-8 (in Russian)]. DOI:10.24884/1561-6274-2005-9-4-84-88
37. Давидов М.И. Сексуальная дисфункция у больных хроническим простатитом и ее коррекция. Урология. 2020;1:51-8 [Davidov MI. Sexual dysfunction in patients with chronic prostatitis and its correction. Urology. 2020;1:51-8 (in Russian)]. DOI:10.18565/urology.2020.1.51-58
________________________________________________
2. Rider JR, Wilson KM, Sinnott JA, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70(6):974-82. DOI:10.1016/j.eururo.2016.03.027
3. Imshinetskaia LP. Seksologiia i andrologiia. Kiev, 1997 (in Russian).
4. Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;1:114. Available at: www. science-education.ru/101-5476. Accessed: 01.03.2023 (in Russian).
5. Nankin HR, Calkins JH. Pituitary-gonadal function during sleep in healthy aging men. Clin Endocr Metab. 1986;63:14.
6. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocr. 1981;4:49-61. DOI:10.1111/j.1365-2265.1981.tb00364.x
7. Udry JR, Billy JO, Morris NM, et al. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil Steril. 1985;43(1):90-4.
8. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990;70(3):792-7. DOI:10.1210/jcem-70-3-792
9. Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;3:39-46 (in Russian).
10. Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021;26(23):7141. DOI:10.3390/molecules26237141
11. Oelke M, Bachmann A, Descazeaud A. Guideline on the Management of Male Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obsruction (BPO). 2012;74.
12. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999;140(3):1481-91. DOI:10.1210/endo.140.3.6585
13. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999;83(5):1213-29. DOI:10.1016/s0025-7125(05)70159-0
14. Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology. 2009;150(10):4594-605. DOI:10.1210/en.2008-1591
15. Kester RR, Mooppan UM, Gousse AE, et al. Pharmacological characterization of isolated human prostate [published correction appears in J Urol. 2003 Dec;170(6 Pt 1):2394]. J Urol. 2003;170(3):1032-8. DOI:10.1097/01.ju.0000080440.74266.b1
16. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339-54. DOI:10.1111/j.1464-410X.2005.05831.x
17. Del Bello F, Bonifazi A, Giorgioni G, et al. Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. Eur J Med Chem. 2019;168:461-73. DOI:10.1016/j.ejmech.2019.02.056
18. Franklin RB, Juang HH, Zou J, Costello LC. Regulation of citrate metabolism by androgen in human prostate carcinoma cells. Endocrine. 1995;3(8)603-7.
19. Costello LC, Liu Y, Zou J, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate. 2000;42(3):196-202. DOI:10.1002/(sici)1097-0045(20000215)42:3<196::aid-pros5>3.0.co;2-8
20. Zhang J, Zhang M, Tang J, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49-57. DOI:10.1038/s41391-020-00277-1
21. Silva RS, Lombardi APG, de Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. Int J Biochem Cell Biol. 2018;96:40-50. DOI:10.1016/j.biocel.2018.01.008
22. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1-13. DOI:10.1196/annals.1386.009
23. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-83. DOI:10.1111/j.1743-6109.2010.01991.x
24. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):157-80.
25. Lee SN, Kraska J, Papargiris M, et al. Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Sci Rep. 2021;11(1):6352. DOI:10.1038/s41598-021-85439-4
26. Corona G, Jannini EA, Mannucci E, et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. 2008;5(8):1991-8.
DOI:10.1111/j.1743-6109.2008.00803.x
27. Godoy A, Montecinos VP, Gray DR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab. 2011;300(2):E263-75. DOI:10.1152/ajpendo.00210.2010
28. Kozlowski R, Kershen RT, Siroky MB, et al. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165(3):1019-26.
29. Uckert S, Kuczyk MA. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. Handb Exp Pharmacol. 2011;202:527-42. DOI:10.1007/978-3-642-16499-6_23
30. Comar VA, Petersen CG, Mauri AL, et al. Influence of the abstinence period on human sperm quality: analysis of 2,458 semen samples. JBRA Assist Reprod. 2017;21(4):306-12. DOI:10.5935/1518-0557.20170052
31. Apostolopoulos V, Bojarska J, Chai TT, et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. DOI:10.3390/molecules26020430
32. Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int J Mol Sci. 2022;23(3):1445. DOI:10.3390/ijms23031445
33. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-8. DOI:10.1016/j.drudis.2014.10.003
34. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700-7. DOI:10.1016/j.bmc.2017.06.052
35. Selkov SA, Petlenko SV, Selkova MS. Use of prostatilene in the combination therapy of chronic prostatitis associated with sexual and reproductive disorders. Andrology and Genital Surgery. 2012;3:97-100 (in Russian).
36. Tkachuk VN, Al-Shukri A, Lotstan-Medvedev AK. Оur experiences with application of vitaprost in chronic prostatitis patients. Nephrology (Saint-Petersburg). 2005;9(4):84-8 (in Russian). DOI:10.24884/1561-6274-2005-9-4-84-88
37. Davidov MI. Sexual dysfunction in patients with chronic prostatitis and its correction. Urology. 2020;1:51-8 (in Russian). DOI:10.18565/urology.2020.1.51-58
Авторы
А.В. Ершов*1,2, Е.Н. Саверская3
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии», Москва, Россия;
3 ФГБОУ ВО «Российский биотехнологический университет (РОСБИОТЕХ)», Москва, Россия
*salavatprof@mail.ru
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Federal Scientific and Clinical Center for Resuscitation and Rehabilitology, Moscow, Russia;
3 Russian Biotechnological University (ROSBIOTECH), Moscow, Russia
*salavatprof@mail.ru
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии», Москва, Россия;
3 ФГБОУ ВО «Российский биотехнологический университет (РОСБИОТЕХ)», Москва, Россия
*salavatprof@mail.ru
________________________________________________
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Federal Scientific and Clinical Center for Resuscitation and Rehabilitology, Moscow, Russia;
3 Russian Biotechnological University (ROSBIOTECH), Moscow, Russia
*salavatprof@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.